Company & Sponsor Intelligence
Kissei Pharmaceutical Co., Ltd.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting0
Completed3
Countries1
Therapeutic footprint
parkinsons
Indexed studies
NCT06722729A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's Disease
parkinsons · JapanPHASE2
parkinsons · JapanPHASE2
NCT03068481Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's Disease
parkinsons · JapanPHASE1
parkinsons · JapanPHASE1
NCT03845387A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.
parkinsons · JapanPHASE2
parkinsons · JapanPHASE2
Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →